YCBD

cbdMD, Inc.
CAPPED RATING

cbdMD, Inc. (YCBD) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B); its weakest is Revisions (F). The rating has held at C- for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.1 / 5.0
C-
Value
B
Factor Score 3.4 / 5.0
Growth
C+
Factor Score 2.7 / 5.0
Profitability
C+
Factor Score 2.6 / 5.0
Momentum
D+
Factor Score 1.7 / 5.0
Revisions
F
Factor Score 0.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 1.6
EV / EBITDA -2.3
Rev Growth YoY 20.6%
Gross Margin 57.7%
Price Return 3M -21.3%
Price Return 12M -51.7%
Catalyst Signal 0.00
Market Cap $5.0M
TTM Revenue $20.9M
Price / Sales 0.2
ROE -40.3%

Historical Factor Score Progression

Held C- for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 B (3.4) C+ (2.7) C+ (2.6) D+ (1.7) F (0.0) C- (2.1)
2026-11-08 B (3.4) C+ (2.8) C+ (2.6) D+ (1.5) F (0.0) C- (2.1)
2026-11-01 B (3.4) C+ (2.7) C+ (2.6) D (1.4) F (0.0) C- (2.1)
2026-10-25 B (3.4) C+ (2.7) C+ (2.6) D (1.3) F (0.0) C- (2.0)
2026-10-18 B (3.4) C+ (2.7) C+ (2.6) D (1.4) F (0.0) C- (2.0)
Page 1 of 3